Zika Virus: Videos & Practice Problems

The Zika virus is an arbovirus belonging to the Flaviviridae family, characterized as an enveloped, single-stranded RNA virus. It is primarily transmitted through the bite of infected Aedes mosquitoes, which are common in tropical and subtropical regions. Besides mosquito bites, Zika can also spread through sexual contact, blood transfusions, and from a pregnant mother to her fetus via the placenta. This multiple transmission routes make it a significant public health concern, especially in areas where Aedes mosquitoes thrive. Understanding these transmission modes is crucial for controlling outbreaks and preventing infection.

Most people infected with the Zika virus are asymptomatic, with only about 20% showing symptoms. When symptoms do occur, they are generally mild and include fever, malaise, joint pain, and rash. The most serious risk is for pregnant individuals, as the virus can cross the placenta and infect the developing fetus. This can lead to microcephaly, a condition where the baby's head is abnormally small due to impaired brain development. Microcephaly can cause lifelong cognitive and coordination impairments. The risk is highest when infection occurs early in pregnancy, making prenatal care and prevention critical in affected regions.

Zika virus infection is diagnosed using reverse transcription polymerase chain reaction (RT-PCR) testing, which detects viral RNA in blood or urine samples. RT-PCR is a nucleic acid amplification test that is highly sensitive and specific for identifying the presence of the virus during the acute phase of infection. Early diagnosis is important for managing symptoms and monitoring pregnant individuals for potential fetal complications. Because many infections are asymptomatic, testing is especially recommended for those with exposure risk or symptoms consistent with Zika virus infection.

Currently, there is no specific antiviral treatment for Zika virus infection. Management is supportive and focuses on relieving symptoms. This includes rest, hydration, and the use of over-the-counter medications to reduce fever and pain, such as acetaminophen. Since the infection is usually mild, most individuals recover without complications. However, for pregnant individuals, there is no treatment to reverse fetal damage caused by the virus. Preventive measures and supportive care remain the main strategies until effective vaccines or therapies become available.

Microcephaly is a congenital condition characterized by an abnormally small head size due to impaired brain development. It is a major concern linked to Zika virus infection during pregnancy, especially when the virus infects the fetus early in gestation. The virus crosses the placenta and disrupts normal brain growth, leading to lifelong cognitive and coordination impairments. Babies born with microcephaly may experience severe learning disabilities and neurological challenges. The 2016 outbreak in Brazil highlighted this association, with thousands of cases reported. Microcephaly is irreversible, emphasizing the importance of preventing Zika infection during pregnancy.

As of now, there are no approved vaccines for the prevention of Zika virus infection. Multiple vaccine candidates are in development, but none have completed the approval process. Infection with Zika virus typically confers long-term immunity, meaning that once infected, individuals are usually protected from future infections. However, because of the severe risks to fetuses during pregnancy, vaccine development remains a high priority to protect vulnerable populations and prevent outbreaks in endemic regions.